Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sorrento Therapeutics Inc SRNE

Healthcare Biotechnology

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G... see more

Add To Watchlist

Recent & Breaking News (GREY:SRNE)

Sorrento Therapeutics to Present at Two Healthcare Conferences

PR Newswire September 5, 2014

Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)

PR Newswire August 26, 2014

Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics

PR Newswire August 18, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors

PR Newswire August 8, 2014

Sorrento Announces the Unexpected Death of its Chief Business Officer

PR Newswire July 31, 2014

Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor

PR Newswire July 21, 2014

Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates

PR Newswire July 1, 2014

BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers

Marketwired June 26, 2014

Morphotek and Sorrento Therapeutics Sign an Exclusive Research and Option Agreement to Generate and Develop Morphotek Antibody Drug Conjugates

PR Newswire June 25, 2014

Sorrento Therapeutics Announces Confidential Submission of Draft Registration Statement for Initial Public Offering (IPO) of its Wholly-owned Subsidiary Ark Animal Health with the SEC

PR Newswire June 23, 2014

Sorrento to Present at BIO Business Forum

PR Newswire June 20, 2014

Sorrento Announces Underwriters' Exercise of Over-Allotment Option

PR Newswire June 12, 2014

Sorrento Therapeutics to Present at Jefferies 2014 Global Healthcare Conference

PR Newswire May 30, 2014

Sorrento Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

PR Newswire May 14, 2014

Sorrento Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire May 14, 2014

Sorrento Announces Transfer of Orphan Drug Designation Sponsorship for Intrathecal Resiniferatoxin from NIH

PR Newswire May 13, 2014

Sorrento appoints Ian Walters as Senior Vice President of Translational Medicine and Corporate Development

PR Newswire April 7, 2014

Sorrento Therapeutics Announces Key Presentation on Cynviloq at the American Association for Cancer Research Annual Meeting

PR Newswire April 4, 2014

Sorrento Announces Presentation of Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting

PR Newswire April 4, 2014